David Resnick is a partner and the co-team leader of the Biotechnology/Chemistry team at Nixon Peabody. David assists clients in obtaining and defending intellectual property protection for cutting edge technologies in the life sciences, including stem cells, regenerative medicine and RNAi. David has developed a particular focus on the areas on pharmacogenomics, proteomics, and disease biomarkers and their application in the evolving field of personalized medicine.
David also assists clients by evaluating their intellectual property portfolios, as well as the intellectual property held by competitors or potential acquisitions or partners. In connection with these activities, he has been involved with strategic patent prosecution, due diligence and freedom-to-operate analyses.
David’s clients include many Boston area universities, research hospitals, and life science startups, as well as large pharmaceutical companies.
It has long been known that different individuals react to the same drug differently. Matching the right therapy with the right individual, commonly know as “personalized medicine,” could improve treatment, reduce... Read more »